JP2022526432A5 - - Google Patents

Info

Publication number
JP2022526432A5
JP2022526432A5 JP2021559932A JP2021559932A JP2022526432A5 JP 2022526432 A5 JP2022526432 A5 JP 2022526432A5 JP 2021559932 A JP2021559932 A JP 2021559932A JP 2021559932 A JP2021559932 A JP 2021559932A JP 2022526432 A5 JP2022526432 A5 JP 2022526432A5
Authority
JP
Japan
Prior art keywords
methyl
phenylboronic acid
pyridine
phenyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526432A (ja
JP7598875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027700 external-priority patent/WO2020210649A1/en
Publication of JP2022526432A publication Critical patent/JP2022526432A/ja
Publication of JP2022526432A5 publication Critical patent/JP2022526432A5/ja
Priority to JP2024209440A priority Critical patent/JP2025027105A/ja
Application granted granted Critical
Publication of JP7598875B2 publication Critical patent/JP7598875B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559932A 2019-04-12 2020-04-10 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体 Active JP7598875B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024209440A JP2025027105A (ja) 2019-04-12 2024-12-02 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833455P 2019-04-12 2019-04-12
US62/833,455 2019-04-12
US201962881111P 2019-07-31 2019-07-31
US62/881,111 2019-07-31
PCT/US2020/027700 WO2020210649A1 (en) 2019-04-12 2020-04-10 Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024209440A Division JP2025027105A (ja) 2019-04-12 2024-12-02 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体

Publications (3)

Publication Number Publication Date
JP2022526432A JP2022526432A (ja) 2022-05-24
JP2022526432A5 true JP2022526432A5 (cg-RX-API-DMAC7.html) 2023-04-18
JP7598875B2 JP7598875B2 (ja) 2024-12-12

Family

ID=70465561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559932A Active JP7598875B2 (ja) 2019-04-12 2020-04-10 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体
JP2024209440A Pending JP2025027105A (ja) 2019-04-12 2024-12-02 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024209440A Pending JP2025027105A (ja) 2019-04-12 2024-12-02 エクトヌクレオチドピロホスファターゼホスホジエステラーゼ1阻害剤としての二環式ヘテロアリール誘導体

Country Status (24)

Country Link
US (2) US12029744B2 (cg-RX-API-DMAC7.html)
EP (2) EP4249070A3 (cg-RX-API-DMAC7.html)
JP (2) JP7598875B2 (cg-RX-API-DMAC7.html)
KR (1) KR102957780B1 (cg-RX-API-DMAC7.html)
CN (2) CN114040915B (cg-RX-API-DMAC7.html)
AU (1) AU2020272034C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020241A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136443A1 (cg-RX-API-DMAC7.html)
DK (1) DK3952995T3 (cg-RX-API-DMAC7.html)
ES (1) ES2960987T3 (cg-RX-API-DMAC7.html)
FI (1) FI3952995T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231413T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064377T2 (cg-RX-API-DMAC7.html)
IL (1) IL286966B2 (cg-RX-API-DMAC7.html)
LT (1) LT3952995T (cg-RX-API-DMAC7.html)
MX (3) MX2021012305A (cg-RX-API-DMAC7.html)
PL (1) PL3952995T3 (cg-RX-API-DMAC7.html)
PT (1) PT3952995T (cg-RX-API-DMAC7.html)
RS (1) RS64792B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110888QA (cg-RX-API-DMAC7.html)
SI (1) SI3952995T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300373T1 (cg-RX-API-DMAC7.html)
TW (2) TWI878284B (cg-RX-API-DMAC7.html)
WO (1) WO2020210649A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022091048A1 (en) 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
CN116724026A (zh) * 2021-01-29 2023-09-08 谛希诺生物科技有限公司 对外核苷酸焦磷酸酶-磷酸二酯酶具有抑制活性的新颖的苯并三唑衍生物及其用途
CA3204409C (en) * 2021-01-29 2026-04-28 Txinno Bioscience Inc. Benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CN117337292A (zh) 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
CN116444544A (zh) * 2022-01-10 2023-07-18 中国科学院上海药物研究所 苯并咪唑类化合物及其医药用途
MX2024009216A (es) * 2022-01-28 2024-08-06 Insilico Medicine Ip Ltd Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CN121248633A (zh) * 2022-11-09 2026-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的环状苯并咪唑衍生物
CN120476128A (zh) * 2023-01-10 2025-08-12 上海翊维康医药有限责任公司 杂芳环化合物及其制备方法和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5240938A (en) 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
GB9020931D0 (en) 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
IE914572A1 (en) 1991-01-17 1992-07-29 Zeneca Ltd Chemical process
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
AU2277201A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel purines
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd 8−ヒドロキシアデニン化合物
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20090264384A1 (en) 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
DE102004060699A1 (de) 2004-12-16 2006-06-22 Ratiopharm Gmbh Verfahren zur Herstellung von Candesartan
ES2308591T3 (es) 2004-12-22 2008-12-01 Algry Quimica, S.L Intermedios para la preparacion de antagonistas de los receptores de la angiotensina ii.
ITMI20050801A1 (it) 2005-05-03 2006-11-04 Dipharma Spa Procedimento per la preparazione di telmisartan
EP1885714B1 (en) 2005-05-24 2014-01-15 LEK Pharmaceuticals d.d. Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl)methyl)-imidazole, dihydroimidazole or benzimidazole derivatives
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
CN100427488C (zh) * 2005-10-21 2008-10-22 上海东升新材料有限公司 腺嘌呤类衍生物及其合成方法
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
JP2009242240A (ja) 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2225210B1 (en) 2007-12-11 2012-04-25 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
EP3246034A1 (en) * 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
WO2010009029A2 (en) 2008-07-15 2010-01-21 Wyeth Methods for the preparation of azole compounds
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
WO2011053247A1 (en) 2009-10-29 2011-05-05 Agency For Science, Technology And Research Method for the detection of an analyte by surface enhanced raman spectroscopy (sers)
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
SI2558577T1 (sl) * 2010-04-16 2019-05-31 Nuevolution A/S Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
MX2013013331A (es) * 2011-05-17 2014-10-17 Principia Biopharma Inc Derivados de azaindol como inhibidores de tirosina-cinasas.
DK2776439T3 (en) 2011-11-09 2018-10-22 Janssen Sciences Ireland Uc PURINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
RU2696572C2 (ru) 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2016036887A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Fluorescence assay for intestinal permeability
US20170305893A1 (en) 2014-10-08 2017-10-26 Thomas Helledays Stiftelse For Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
WO2016200840A1 (en) 2015-06-08 2016-12-15 Cleave Biosciences, Inc. Mono and bicyclic ring boronic acid, ester and salt compounds as inhibitors of p97 complex
MX375424B (es) * 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
WO2018119328A1 (en) * 2016-12-22 2018-06-28 Mavupharma, Inc. Phosphodiesterase inhibitors and methods of microbial treatment
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
EA202090595A1 (ru) 2017-09-08 2020-06-29 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Ингибиторы enpp1 и способы модуляции иммунного ответа
WO2019096113A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种氘代的含硼的化合物及药物组合物和用途
CN108409767B (zh) 2018-04-13 2020-07-10 上海泰坦科技股份有限公司 一种杂环联苯硼酸的制备方法
US20220056052A1 (en) 2018-12-28 2022-02-24 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
MX2021009269A (es) 2019-02-01 2021-08-24 Univ Leland Stanford Junior Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
WO2020191501A1 (en) 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
CA3151277A1 (en) 2019-09-16 2021-03-25 Aten Porus Lifesciences Pvt. Ltd. 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein
WO2021061803A1 (en) 2019-09-23 2021-04-01 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
WO2021133915A1 (en) 2019-12-23 2021-07-01 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
WO2021203772A1 (en) 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof

Similar Documents

Publication Publication Date Title
US10399951B2 (en) Compounds and compositions for inhibition of FASN
JP5865519B2 (ja) イミダゾピロリジノン化合物
DK2935248T3 (en) RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
ES2806135T3 (es) Nuevos inhibidores de bromodominios bicíclicos
CA2189143A1 (en) A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain
JP2006520805A5 (cg-RX-API-DMAC7.html)
ES2774517T3 (es) Moduladores del receptor nuclear (ROR) para el tratamiento de enfermedades inflamatorias y autoinmunes
JP2019529529A (ja) 細胞代謝過程の阻害剤
JP2010515733A5 (cg-RX-API-DMAC7.html)
ME02514B (me) Derivati 8 -karbamoil- 2-(2,3-disupstituirani pirid-6- il)-1,2,3,4-tetrahidroizokinolina kao sredstva za izazivanje apoptoze za liječenje karcinoma i imunih i autoimunih bolesti
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2016106112A (ja) ベンゾチアゾール−6−イル酢酸誘導体およびhiv感染を処置するためのそれらの使用
IL300702A (en) 1H-BENZO[D]IMIDAZOLE derivatives as TLR9 inhibitors for the treatment of fibrosis
TW200410689A (en) Synergistic methods and compositions for treating cancer
JP2012532931A5 (cg-RX-API-DMAC7.html)
JP2013523884A5 (cg-RX-API-DMAC7.html)
JP2013515033A5 (cg-RX-API-DMAC7.html)
JP2012515787A5 (cg-RX-API-DMAC7.html)
US11802120B2 (en) Fused cyclic urea derivatives as CRHR2 antagonist
KR20160030541A (ko) 벤질-1H-피라졸로[3,4-b]피리딘 및 그의 용도
JP2015535226A (ja) ブルートンチロシンキナーゼの阻害剤
JP2023538619A5 (cg-RX-API-DMAC7.html)
JP2018520096A5 (cg-RX-API-DMAC7.html)
JP2018501209A5 (cg-RX-API-DMAC7.html)
FI3952995T3 (fi) Bisyklisiä heteroaryylijohdannaisia ektonukleotidipyrofosfataasifosfodiesteraasi-1:n inhibiittoreina